Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of a novel class of medicines known as Bicycle® molecules. These fully synthetic peptides are constrained with small molecule scaffolds to form two loops, stabilising their structural geometry. This design facilitates high-affinity and selective target binding, combining the pharmacological benefits typically associated with biologics with the manufacturing and pharmacokinetic advantages of small molecules
The company’s mission is to create unique, impactful medicines that transform the lives of the largest possible number of patients. While their primary focus is on developing treatments for solid tumour cancers, Bicycle Therapeutics is also exploring applications of their technology in other therapeutic areas with significant unmet medical needs.
Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, UK, with key functions and members of its leadership team also located in Cambridge, Massachusetts, USA.
